Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells

Molecular Cancer Therapeutics

Volumn 12, Issue 5, 2013, Pages 737-746

  Shibata, Tomohiro ^a   Kan, Hitoshi ^a   Murakami, Yuichi ^a,c   Ureshino, Hiroki ^a   Watari, Kosuke ^a   Kawahara, Akihiko ^d   Kage, Masayoshi ^d   Hattori, Satoshi ^e   Ono, Mayumi ^a   Kuwano, Michihiko ^b  

^a Department of Pharmaceutical Oncology ^*  (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c ST MARY S HOSPITAL   (Japan)

^d KURUME UNIVERSITY HOSPITAL   (Japan)

^e KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; IRINOTECAN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN KINASE B; Y BOX BINDING PROTEIN 1;

ARTICLE; CANCER RESISTANCE; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; Y-BOX-BINDING PROTEIN 1;

EID: 84877646454     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1125     Document Type: Article

References (43)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
4. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007;369:29-36.
5. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991;51:1034-38.
6. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
7. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immune-sorbent assay. Int J Cancer 2002;98:833-7.
8. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8.
9. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9.
10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. ToGA trial investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010;376: 687-97.
11. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
12. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007;6:667-74.
13. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-43.
14. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010;16:1509-19.
15. Matsumoto K, Wolffe AP. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol 1998;8: 318-23.
16. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003;25: 691-8.
17. Lu ZH, Books JT, Ley TJ. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 2005;25:4625-37.
18. Uchiumi T, Fotovati A, Sasaguri T, Shibahara K, Shimada T, Fukuda T, et al. YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation. J Biol Chem 2006;281: 40440-9.
19. Fotovati A, Abu-Ali S, Wang P, Deleyrolle L, Lee C, Triscott J, et al. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res 2011;71:5569-78.
20. Bergmann S, Royer-Pokora B, Fietze E, J€urchott K, Hildebrandt B, Trost D, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005;65:4078-87.
21. Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, et al. Aktdependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2006;19:2736-46.
22. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004;3:1485-92.
23. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003;278:27988-96.
24. Chatterjee M, Rancso C, St€uhmer T, Eckstein N, Andrulis M, Gerecke C, et al. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 2008;111:3714-22.
25. Basaki Y, Taguchi K, Izumi H, Murakami Y, Kubo T, Hosoi F, et al. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. Eur J Cancer 2010;46:954-65.
26. Astanehe A, Finkbeiner MR, Krzywinski M, Fotovati A, Dhillon J, Berquin IM, et al. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 2012;31:4434-46.
27. Sakura H, Maekawa T, Imamoto F, Yasuda K, Ishii S. Twohuman genes isolated by a novel method encode DNA-binding proteins containing a common region of homology. Gene 1988;73:499-507.
28. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006;66:4872-9.
29. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 2007;9:R61.
30. Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, et al. Expression of HER2 and estrogen receptor a depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 2008;68:1504-12.
31. Kashihara M, Azuma K, Kawahara A, Basaki Y, Hattori S, Yanagawa T, et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol 2009;4:1066-74.
32. Hyogotani A, Ito KI, Yoshida K, Izumi H, Kohno K, Amano J. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer. Clin Lung Cancer 2012;13:375-84.
33. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, J€urchott K, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, UPA and PAI-1. Int J Cancer 2002;97:278-82.
34. Ureshino H, Murakami Y, Watari K, Izumi H, Kawahara A, Kage M, et al. N-myc downstream regulated gene 1 (NDRG1) promotes metastasis of human scirrhous gastric cancer cells through epithelial mesenchymal transition. PLoS One 2012;7:e41312.
35. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996;56:4224-8.
36. Tanizaki J, Okamoto I, Takezawa K, Tsukioka S, Uchida J, Kiniwa M, et al. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 2010;9: 1198-207.
37. Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y, et al. Targeted disruption of one allele of the Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. Cancer Sci 2004;95: 348-53.
38. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
39. Wu Y, Yamada S, Izumi H, Li Z, Shimajiri S, Wang KY, et al. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. J Surg Oncol 2012;105:724-30.
40. Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005; 65:4253-60.
41. Engelman JA, J€anne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide3-kinase activity in gefitinibsensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93.
42. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12:4103-11.
43. Tabara K, Kanda R, Sonoda K, Kubo K, Murakami Y, Kawahara A, et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE 2012;7:e41017.